3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Peritoneal Neoplasms
1
Colorectal Neoplasms
1
Interventions
Oxaliplatin
1004
Fluorouracil
800
Capecitabine
764
Gemcitabine
650
Leucovorin
559
Irinotecan
537
Bevacizumab
513
Radiotherapy
460
Cisplatin
440
Drug Therapy
298
Cetuximab
280
Surgical Procedures, Operative
229
Paclitaxel
228
S 1 (combination)
217
pembrolizumab
205
Docetaxel
199
130-nm albumin-bound paclitaxel
196
Nivolumab
193
sintilimab
191
Radiosurgery
190
lenvatinib
180
Folfox protocol
179
Sorafenib
178
Albumin-Bound Paclitaxel
173
apatinib
170
tislelizumab
161
camrelizumab
160
Neoadjuvant Therapy
158
Blood Specimen Collection
154
durvalumab
148
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
MOC31PE immunotoxin
×
Gastrointestinal
×
Clear all
NCT02219893
2017-05-30
ImmunoPeCa
Oslo University Hospital
Phase 1/2
Completed
15 enrolled